US 12,465,652 B2
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
Kenneth W. Walker, Newbury Park, CA (US); Jerry Ryan Holder, Simi Valley, CA (US); David J. Lloyd, Thousand Oaks, CA (US); Shu-Chen Lu, Thousand Oaks, CA (US); Murielle M. Veniant-Ellison, Thousand Oaks, CA (US); and Shanaka Stanislaus, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 16/623,756
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Jun. 20, 2018, PCT No. PCT/US2018/038634
§ 371(c)(1), (2) Date Dec. 17, 2019,
PCT Pub. No. WO2018/237095, PCT Pub. Date Dec. 27, 2018.
Claims priority of provisional application 62/523,216, filed on Jun. 21, 2017.
Prior Publication US 2020/0384119 A1, Dec. 10, 2020
Int. Cl. A61K 47/65 (2017.01); C07K 14/72 (2006.01); C07K 16/26 (2006.01)
CPC A61K 47/65 (2017.08) [C07K 14/72 (2013.01); C07K 16/26 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
 
1. A glucagon like polypeptide-1 (GLP-1) receptor agonist, wherein said agonist comprises the amino acid sequence of SEQ ID NO: 3239.